Korea Arlico Pharm
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Korea Arlico Pharm makes prescription and over-the-counter medicines, tablets, capsules, and other drug formulations, used by patients and dispensed through hospitals and pharmacies in South Korea and exported abroad.
Listed on KOSDAQ, South Korea's small-cap board, it supplies domestic healthcare channels, provides contract manufacturing (producing medicines on behalf of other pharmaceutical companies), and exports finished drugs and health-related products overseas. Its business spans four main lines: domestic drug sales, contract manufacturing, international exports, and medical devices alongside health-functional foods and cosmetics.
Summary is AI-generated and may contain errors · figures from DART filings
The company operates its own central research laboratory, relocated and expanded to Gwangyo, focused on developing improved new drugs and differentiated drug formulations.
Korea Arlico Pharm in five facts
What does Korea Arlico Pharm do?
Korea Arlico Pharm makes prescription and over-the-counter medicines, tablets, capsules, and other drug formulations, used by patients and dispensed through hospitals and pharmacies in South Korea and exported abroad.
Where is Korea Arlico Pharm listed and in which sector?
Korea Arlico Pharm (Korean name: 알리코제약) trades under KRX code 260660 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is Korea Arlico Pharm?
Its market capitalisation was US$24.6M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Korea Arlico Pharm's latest annual revenue and operating profit?
For fiscal year 2025, Korea Arlico Pharm reported revenue of US$151.9M, operating profit of US$746.6K and a net loss of US$456.9K, per its annual report on DART (data retrieved from DART on 2026-10-02). Revenue was up 5.7% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-10-02
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Report on securities held by executives/major shareholdersOct 15
- Change of CEOSep 11
- [Attachment added] Results of extraordinary shareholders' meetingSep 11
- Appointment/dismissal/resignation of an independent directorSep 11
- Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Korea Arlico Pharm reported separate results for FY2025: revenue of US$140M (+6.1% year on year), operating profit of US$999K (from a loss a year earlier) and a net loss of US$167K.
Earnings · Feb 12 - Cash/in-kind dividend decision
Korea Arlico Pharm declared a cash dividend of US$0.05 per share.
Dividend · Feb 12 - Early redemption of convertible bonds (incl. overseas CBs)Capital raise · Feb 10